TD Cowen Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $60
Analysts Offer Insights on Healthcare Companies: Merus (MRUS) and BridgeBio Pharma (BBIO)
Express News | BridgeBio Pharma Inc : Mizuho Raises Target Price to $60 From $53
Mizuho Securities Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Announces Target Price $60
Alnylam Delivers Q1 Surprise, Analysts Highlight Amvuttra Momentum, Limited Tariff Risk
Express News | Form 144 | BridgeBio Pharma(BBIO.US) Director Proposes to Sell 3.52 Million in Common Stocks
BridgeBio Pharma Call Volume Above Normal and Directionally Bullish
BridgeBio Pharma, Inc. (NASDAQ:BBIO) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
Evercore Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Raises Target Price to $70
Scotiabank Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Raises Target Price to $55
UBS Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Raises Target Price to $72
BridgeBio Pharma Stock (BBIO) Jumps on Strong Drug Launch
Why BridgeBio Pharma, Inc. (BBIO) Surged on Wednesday
BridgeBio Pharma's Earnings Call Highlights Success and Growth
BridgeBio Pharma Is Maintained at Overweight by Piper Sandler
BridgeBio Pharma Analyst Ratings
Express News | BridgeBio Pharma Shares up 6.1% After Q1 Sales of Heart Condition Drug Beat Estimates
UBS Adjusts Price Target on BridgeBio Pharma to $72 From $65, Maintains Buy Rating
A Quick Look at Today's Ratings for BridgeBio Pharma(BBIO.US), With a Forecast Between $50 to $67
BridgeBio Pharma, Inc.'s (NASDAQ:BBIO) Business Is Yet to Catch Up With Its Share Price